Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Co-expression of SOX2 and HR-HPV RISH predicts poor prognosis in small cell neuroendocrine carcinoma of the uterine cervix

Fig. 3

Kaplan-Meier survival curves for OS and DFS of small cell neuroendocrine carcinoma of the uterine cervix (SCNEC) cases according to SOX2, P16INK4A, and high-risk-human papilloma virus (HR-HPV) RISH expression. ac OS according to SOX2, P16INK4A, and HR-HPV RISH expression status in patients with SCNEC. d OS according to a combination of SOX2/P16INK4A co-expression. Group AI: SOX2Low/P16INK4A-; Group AII: SOX2High/P16INK4A- or SOX2Low/P16INK4A+; Group AIII: SOX2High/P16INK4A+. e OS according to a combination of SOX2- IHC/HR-HPV RISH co-expression. Group BI: SOX2Low/HR-HPV RISH-; Group BII: SOX2High/HR-HPV RISH- or SOX2Low/HR-HPV RISH+; Group BIII: SOX2High/HR-HPV RISH+. fh DFS according to SOX2, P16INK4A, and HR-HPV RISH expression status in patients with SCNEC. i DFS according to a combination of SOX2/P16INK4A co-expression. Group AI: SOX2Low/P16INK4A-; Group AII: SOX2High/P16INK4A- or SOX2Low/P16INK4A+; Group AIII: SOX2High/P16INK4A+. j DFS according to a combination of SOX2- IHC/HR-HPV RISH co-expression. Group BI: SOX2Low/HR-HPV RISH-; Group BII: SOX2High/HR-HPV RISH- or SOX2Low/HR-HPV RISH+; Group BIII: SOX2High/HR-HPV RISH+

Back to article page